The development of EGFR tyrosine kinase inhibitors (TKIs) in the 2000s resulted in dramatic improvements in both the response rate (RR) and progression-free survival (PFS) over traditional chemotherapy for late-stage NSCLC patients who harbor susceptible EGFR mutations [7,8,9,10,11,12], and EGFR-TKIs have become the standard of care for these patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.